Umbilical cord blood source hematopoietic stem cell in-vitro amplification culture system and method
By using a combination of cytokines and mesenchymal stem cell exosomes or small molecule compounds in the in vitro expansion culture system of cord blood-derived hematopoietic stem cells, the problem of low proliferation rate of in vitro expansion culture medium of umbilical cord blood hematopoietic stem cells was solved, and the problem of low proliferation rate of in vitro expansion culture medium of umbilical cord blood was achieved. The efficient amplification and dry maintenance of hematopoietic stem cells reduces costs and avoids potential inflammatory responses.
Patent Information
- Application Number
- CN202411183836.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, the cell proliferation rate of umbilical cord blood hematopoietic stem cell in vitro expansion medium is low, and the implantation ability and hematopoietic reconstruction ability are insufficient, and there are problems such as gene mutations, high cytokine cost, and potential toxicity of polymers. , it is difficult to effectively amplify hematopoietic stem cells.
A system of in vitro expansion of hematopoietic stem cells from umbilical cord blood was designed, using basal culture medium, cytokine combinations and mesenchymal stem cell exosomes or small molecule compound ATRA, including TPO, SCF, Flt3-L, IL- 3. IL-6, MSC-Exo and ATRA, adjust the concentration of each factor to promote the proliferation of hematopoietic stem cells and maintain dryness.
It significantly improves the transplantation and implantation ability of hematopoietic stem cells and the reconstruction ability of the hematopoietic system, maintains stemness, avoids the inflammatory reaction caused by polymers, and achieves efficient hematopoietic stem cell expansion, reduces costs, and ensures the purity of the cells and Physiological properties.
Smart Images

Figure CN119040263A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of stem cell technology cultivation, and in particular to an in vitro expansion and cultivation system and method for hematopoietic stem cells derived from umbilical cord blood. Background Art
[0002] Hematopoietic stem cells (HSCs) are adult stem cells in the blood system, which have two major characteristics, self-renewal and multi-lineage differentiation, making these cells an attractive source for stem cell therapy. Hematopoietic stem cell transplantation can save lives in the treatment of a wide range of diseases, including blood diseases, immune diseases and genetic diseases. Bone marrow and mobilized peripheral blood stem cells are the most common sources of hematopoietic stem cells for transplantation; however, their use is limited by the low availability of suitable human leukocyte antigen (HLA) matched donors. An alternative approach allows the use of more quickly obtained partially mismatched donors and involves the use of umbilical cord blood (UCB), which has been shown to be a rich source of hematopoietic stem cells. However, the number of stem cells in a single UCB unit is insufficient for transplantation into adults. These two problems, namely the lack of matched donors and the low number of stem cells available for transplantation from common HSCs sources, especially in the case of UCB, severely limit HSCs transplantation. Clinical experience has shown that stem cell dose (measured as CD34+ cell count) is associated with patient survival and the time required for engraftment, suggesting that the expansion of hematopoietic stem and progenitor cells is expected to be highly beneficial for their clinical application.
[0003] Bone marrow, peripheral blood and umbilical cord blood are important sources of hematopoietic stem cells. Umbilical cord blood has the advantages of easy collection, rich stem cell content and low incidence of graft-versus-host disease, making it an important source of stem cells for hematopoietic reconstruction. Although umbilical cord blood hematopoietic stem cells are richer than bone marrow hematopoietic stem cells, their number cannot meet clinical needs, especially when hematopoietic stem cell transplantation is performed on patients with larger body weight, transplantation delays often occur due to insufficient hematopoietic stem cells. Therefore, finding a safe and effective method for in vitro expansion of hematopoietic stem cells so that their number meets clinical needs is a problem that needs to be solved urgently.
[0004] At present, the main approaches to studying the in vitro expansion of hematopoietic stem cells can be summarized into the following four categories:
[0005] First, editing the genes related to hematopoietic stem cell self-renewal through gene editing technology to make them highly expressed in vitro can achieve efficient in vitro expansion of hematopoietic stem cells. However, this scheme has a serious drawback that it is prone to gene mutation, which may lead to serious or even fatal consequences in clinical applications.
[0006] Secondly, the effect of increasing the expansion can be achieved by stimulating the hematopoietic stem cells expanded in vitro with various cytokines, but the efficiency is limited and the application cost of cytokines is high.
[0007] Third, by adding small molecule compounds to stimulate the in vitro expansion of hematopoietic stem cells, the purpose of improving their expansion efficiency can be achieved, but it also has the problem of high cost;
[0008] Fourthly, the use of related polymers and other materials to simulate the in vivo hematopoietic microenvironment can greatly improve the expansion efficiency of hematopoietic stem cells. However, this scheme for culturing hematopoietic stem cells has potential toxicity, and clinical applications may result in problems such as immune inflammatory responses.
[0009] Today, the biggest challenge for the in vitro expansion of hematopoietic stem cells remains how to integrate various cell-intrinsic and extrinsic signals into the regulatory network that controls the fate outcome of HSCs and to decipher how these factors are interconnected. It is likely that the balance of various co-regulatory stimuli, acting simultaneously or sequentially, is crucial for the fate outcome of HSCs, and the ability to mimic these signals may determine the success of in vitro stem cell expansion protocols. Summary of the invention
[0010] The purpose of the present invention is to provide an in vitro expansion culture system and method for hematopoietic stem cells derived from umbilical cord blood in order to address the defects of low cell proliferation rate in the in vitro expansion culture medium of umbilical cord blood hematopoietic stem cells in the prior art, as well as low engraftment ability and hematopoietic reconstruction ability of the umbilical cord blood hematopoietic stem cells cultured in vitro when transplanted into a recipient. The culture system used in the present invention can significantly improve the engraftment ability of hematopoietic stem cells transplanted into a recipient, the reconstruction ability of the hematopoietic system and the hematopoietic stem cell proliferation rate, and can better maintain the stemness of the hematopoietic cells.
[0011] To achieve the above purpose, the technical solution designed by the present invention is as follows:
[0012] The present invention provides an in vitro expansion culture system of hematopoietic stem cells derived from umbilical cord blood, wherein the in vitro expansion culture system of hematopoietic stem cells consists of a basal culture medium, a cytokine combination and an additive; the additive is a mesenchymal stem cell exosome MSC-Exo or a small molecule compound ATRA or a combination of mesenchymal stem cell exosome MSC-Exo and a small molecule compound ATRA; the cytokine combination is TPO, SCF, Flt3-L, IL-3 and IL-6; the concentration of each component is:
[0013] TPO: 50-100ng / mL, SCF: 50-100ng / mL, Flt3-L: 50-100ng / mL, IL-3: 10-20ng / mL, IL-6: 10-30ng / mL, MSC-Exo: 50-200μg / mL and ATRA: 10-50nM.
[0014] Furthermore, the additive is mesenchymal stem cell exosomes MSC-Exo or a small molecule compound ATRA or a combination of mesenchymal stem cell exosomes MSC-Exo and a small molecule compound ATRA, and the concentration of each component in the hematopoietic stem cell in vitro expansion culture system is:
[0015] TPO: 50-70ng / mL, SCF: 50-70ng / mL, Flt3-L: 50-80ng / mL, IL-3: 8-15ng / mL, IL-6: 5-15ng / mL, MSC-Exo: 100-150μg / mL, ATRA: 20-30nM.
[0016] Furthermore, the hematopoietic stem cell in vitro expansion culture system is composed of a basal culture medium, a cytokine combination and an additive; the additive is a combination of mesenchymal stem cell exosomes MSC-Exo and a small molecule compound ATRA, and the concentration of each component in the hematopoietic stem cell in vitro expansion culture system is:
[0017] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL, ATRA: 30nM.
[0018] Furthermore, the hematopoietic stem cell in vitro expansion culture system is composed of a basal culture medium, a cytokine combination and mesenchymal stem cell exosomes MSC-Exo; the concentration of each component in the hematopoietic stem cell in vitro expansion culture system is:
[0019] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL.
[0020] Furthermore, the hematopoietic stem cell in vitro expansion culture system is composed of a basal culture medium, a cytokine combination and a small molecule compound ATRA; the concentration of each component in the hematopoietic stem cell in vitro expansion culture system is:
[0021] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL, ATRA: 30nM.
[0022] Furthermore, the basal culture medium is a serum-free culture medium.
[0023] Furthermore, the serum-free culture medium is selected from StemSpanTM SFEM, IMDM, DMEM / F-12, RPMI1640 and HyClone Advance STEM.
[0024] The present invention also provides a method for in vitro expansion and culture of hematopoietic stem cells derived from human umbilical cord blood, comprising the following steps:
[0025] (1) Isolating mononuclear cells from human umbilical cord blood samples: pre-treating the human umbilical cord blood sample, and then sequentially resuspending, centrifuging, extracting, washing, and resuspending to obtain a mononuclear cell suspension;
[0026] (2) Magnetic bead separation of CD34 + Cells: Count and resuspend the mononuclear cell suspension, add CD34 MicroBeads and PCR Blocking Reagent to the cell suspension, incubate at 4°C for 30 min, and then pass through the column for CD34 + Positive sorting, CD34 + Cell suspension with high proportion (increase CD34 + The purity of cells can be determined by + The cell suspension was passed through the column again to obtain CD34 + A higher percentage of cell suspension);
[0027] (3) Expansion and culture of CD34 + cell:
[0028] CD34 obtained in the resuspension step (2) of the hematopoietic stem cell in vitro expansion culture system + The cell suspension with a high proportion is inoculated into a cell culture flask for culture and expansion.
[0029] Principle of the present invention:
[0030] 1. The in vitro expansion culture system for hematopoietic stem cells provided by the present invention is composed of a basic culture medium, cytokines, mesenchymal stem cell exosomes and small molecule compounds. Therefore, the above combination can promote the proliferation of hematopoietic stem cells while effectively maintaining the stemness of hematopoietic stem cells. Compared with the in vitro expansion culture system in the related art, the in vitro expansion culture system for hematopoietic stem cells provided by the present invention can effectively avoid the incorporation of heterogeneous substances brought by polymer materials, so that the in vitro expanded hematopoietic stem cells are more suitable for transplantation without causing related inflammatory reactions, etc. The changes in the expression of the cell genome and proteome make the characteristics of hematopoietic stem cells closer to the original state in the body. The hematopoietic stem cells obtained by culturing the in vitro expansion culture system provided by the present invention are used for scientific research-level hematopoietic stem cell research, which can make the scientific research results more real and closer to the actual situation of the organism.
[0031] Under certain conditions, hematopoietic stem cells are a type of cell that can proliferate indefinitely in vitro. However, they will be affected by various external factors, and hematopoietic stem cells will lose their stemness and thus lose their ability to differentiate in multiple directions. Current research on hematopoietic stem cells, especially in vitro culture of hematopoietic stem cells, requires large-scale expansion while maintaining the stemness of hematopoietic stem cells as much as possible. Most of the current studies on in vitro expansion of hematopoietic stem cells use cytokines to stimulate cell division and proliferation. However, this experimental approach often causes the loss of cell stemness, causing hematopoietic stem cells to differentiate. In addition, some other researchers have attempted to use materials such as polymers to build an environment that simulates the physiological conditions in the body for in vitro expansion of hematopoietic stem cells, so as to maintain the stemness of hematopoietic stem cells in vitro. However, the new materials introduced by this method have become a potential risk of inflammatory recurrence in clinical practice. This is also an important factor hindering the clinical application of this method.
[0032] In summary, the present invention proposes an in vitro expansion culture system for hematopoietic stem cells, in which a small molecule compound ATRA combined with mesenchymal stem cell exosomes is added to the culture system combined with a cytokine combination. The experimental results show that the in vitro expansion culture system for hematopoietic stem cells can efficiently expand hematopoietic stem cells in vitro. In addition, the culture system also effectively maintains the stemness of hematopoietic stem cells, providing safe and reliable cell culture conditions for in vitro culture research of hematopoietic stem cells.
[0033] 2. The present invention adjusts the amount of each factor added in the cytokine combination, introduces a small molecule compound all-trans retinoic acid and mesenchymal stem cell exosomes at the same time, and controls the concentration of each factor within the above range, so that the practical performance of the in vitro expansion culture system of hematopoietic stem cells is more excellent, and the CD34 with the original biological characteristics of hematopoietic stem cells is more excellent. + More cells were obtained, among which,
[0034] a.TPO (thrombopoietin) is a cytokine that promotes platelet production and has a good stimulating effect on the growth and differentiation of megakaryocytes;
[0035] b. SCF (stem cell growth factor) can promote the proliferation and differentiation of early hematopoietic precursor cells. When used in combination with TPO, it can significantly expand hematopoietic stem cells.
[0036] c. Flt3-L (tyrosine kinase 3 receptor) is secreted by bone marrow stromal stem cells and other cells, and can cooperate with other growth factors to promote the proliferation of stem cells;
[0037] d.IL-3 (interleukin-3) is produced by T lymphocytes and can stimulate the proliferation, differentiation and function of cells involved in immune responses;
[0038] e.IL-6 (interleukin-6) can regulate the growth and differentiation of a variety of cells, and has the function of regulating immune response, acute phase reaction and hematopoiesis;
[0039] f. MSC-Exo (mesenchymal stem cell exosomes) are a type of small membrane vesicles containing complex RNA and proteins, with a diameter of usually 50-200nm. It contains rich information and is the main component of intercellular communication;
[0040] g. ATRA (all-trans retinoic acid) is a derivative of vitamin A (retinol), usually present in serum at low physiological concentrations. It is a naturally occurring small molecule that has been shown to play an important role in the development, differentiation and homeostasis of various cell types. The present invention uses the above-mentioned multiple cytokines and small molecule compounds to jointly regulate the survival and proliferation of hematopoietic stem cells, while maintaining the stemness of hematopoietic stem cells, so that hematopoietic stem cells have a good ability to differentiate.
[0041] 3. The present invention uses serum-free culture medium as the basic culture medium of the in vitro expansion culture system of hematopoietic stem cells, which effectively avoids the introduction of exogenous animal-derived impurities and infection risks, thereby enabling hematopoietic stem cells to maintain their original characteristics well, improve the expression level of stemness genes of hematopoietic stem cells, and easily obtain a hematopoietic stem cell population with higher purity; wherein, StemSpan TM SFEM is a serum-free culture medium with excellent proliferation and differentiation effects, and is very suitable for the development of hematopoietic stem cells in the culture system.
[0042] 4. The present invention adopts an in vitro expansion and culture system for hematopoietic stem cells to carry out in vitro expansion and culture of hematopoietic stem cells, which can not only achieve the proliferation of hematopoietic stem cells, but also effectively maintain the stemness and original physiological characteristics of hematopoietic stem cells, close to their original state in the body. Therefore, the hematopoietic stem cells obtained by the in vitro expansion and culture method provided by the present invention are used for scientific research-level experimental research, which can effectively ensure the authenticity and reliability of the experimental results.
[0043] 5. Hematopoietic stem cells derived from human umbilical cord blood have low immunogenicity, low matching requirements, and excellent hematopoietic performance, but their quantity is very limited. Therefore, the present invention uses human umbilical cord blood, which is easy to collect and rich in sources, to extract hematopoietic stem cells and culture and expand them in vitro, so that hematopoietic stem cells with high stemness and good preservation of the original physiological characteristics of the cells can be obtained at a low cost.
[0044] Beneficial effects of the present invention:
[0045] 1. The present invention further controls the concentration of each factor in the cytokine combination within the following range: TPO: 50-100 ng / mL, SCF: 50-100 ng / mL, Flt3-L: 50-100 ng / mL, IL-3: 10-20 ng / mL, IL-6: 10-30 ng / mL, and the obtained hematopoietic stem cell in vitro expansion culture system has a better effect on maintaining the stemness of hematopoietic stem cells.
[0046] 2. The present invention introduces the application method of mesenchymal stem cell exosomes combined with ATRA, and the small molecule is used in combination with the existing cytokine combination scheme to show CD34 + The cells can be more efficiently expanded and the original stemness of the cells can be better maintained. The concentration of mesenchymal stem cell exosomes is controlled within the following range: 100-200 μg / mL, and the concentration of ATRA is controlled within the following range: 20-30 nM.
[0047] 3. The present invention adopts a serum-free culture medium, which effectively avoids the introduction of exogenous animal-derived impurities and infection risks, thereby enabling hematopoietic stem cells to maintain their original characteristics well, improving the expression level of hematopoietic stem cells, and making it easier to obtain a high-purity hematopoietic stem cell population.
[0048] 4. The gene expression of hematopoietic stem cells obtained by using the hematopoietic stem cell in vitro expansion culture system provided by the present invention will not change, and it is close to the hematopoietic stem cells in the physiological state. Therefore, the experimental results of using the above hematopoietic stem cells for scientific research applications are true and reliable.
[0049] 5. The present invention utilizes human umbilical cord blood, which is easy to collect and widely available, to separate hematopoietic stem cells and culture and expand them in vitro, thereby being able to obtain hematopoietic stem cells with high stemness and good effects in maintaining the original physiological characteristics of the cells at a low cost.
[0050] 6. The present invention utilizes the easily accessible and widely available human umbilical cord source to culture mesenchymal stem cells, and then obtains stem cell exosomes through gradient centrifugation and ultra-high-speed centrifugation. This method obtains rich and high-quality mesenchymal stem cells without harming the donor. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 The results of flow cytometric analysis of a cell suspension obtained by the method for separating hematopoietic stem cells from umbilical cord blood provided by the present invention; the cell suspension is used for inoculation on day 0 of different system culture schemes of comparative example 1 and embodiments 1 to 3;
[0052] In the figure, Q5-1 represents CD34 - CD38 + Cell population, Q5-2 indicates CD34 + CD38 + Cell population, Q5-3 indicates CD34 - CD38 - Cell population, Q5-4 indicates CD34 + CD38 - Cell population.
[0053] Figure 2 (a)(b)(c)(d) are flow cytometric test results of hematopoietic stem cells amplified on the 10th day using the hematopoietic stem cell in vitro amplification culture systems provided by Comparative Example 1 (D1), Example 1, Example 2 and Example 3, respectively;
[0054] In the figure, Control represents the expansion culture system D1, ATRA represents the expansion culture system 1, MSC Exo represents the expansion culture system 2, and MSC Exo+ATRA represents the expansion culture system 3. In addition, in this flow chart, Q5-1 represents CD34 - CD38 + Cell population, Q5-2 indicates CD34 + CD38 + Cell population, Q5-3 indicates CD34 - CD38 - Cell population, Q5-4 indicates CD34 + CD38 - Cell population.
[0055] Figure 3The diagram is a statistical result of counting the total nucleated cells (TNCs) on days 0, 5, and 10 of culturing hematopoietic stem cells using the in vitro hematopoietic stem cell expansion culture systems provided in Examples 1-3 and Comparative Example 1, respectively;
[0056] In the figure, Control represents the expansion culture system D1, ATRA represents the expansion culture system 1, MSC Exo represents the expansion culture system 2, and MSC Exo+ATRA represents the expansion culture system 3.
[0057] Figure 4 The hematopoietic stem cell in vitro expansion culture system provided in Examples 1-3 and Comparative Example 1 was used to expand and culture the hematopoietic stem cells on the 10th day. + Statistical results of cell counting;
[0058] In the figure, Control represents the expansion culture system D1, ATRA represents the expansion culture system 1, MSC Exo represents the expansion culture system 2, and MSC Exo+ATRA represents the expansion culture system 3.
[0059] Figure 5 The hematopoietic stem cells were cultured in vitro using the hematopoietic stem cell expansion and culture systems provided in Examples 1-3 and Comparative Example 1, and CD34 + CD38 - Statistical results of cell counting;
[0060] In the figure, Control represents the expansion culture system D1, ATRA represents the expansion culture system 1, MSC Exo represents the expansion culture system 2, and MSC Exo+ATRA represents the expansion culture system 3.
[0061] Figure 6 The hematopoietic stem cells were cultured in vitro using the hematopoietic stem cell expansion and culture systems provided in Examples 1-3 and Comparative Example 1, and CD34 + CD38 - Lin - Statistical results of cell counting;
[0062] In the figure, Control represents the expansion culture system D1, ATRA represents the expansion culture system 1, MSC Exo represents the expansion culture system 2, and MSC Exo+ATRA represents the expansion culture system 3.
[0063] Figure 7 On the 10th day of the hematopoietic stem cell in vitro expansion and culture method provided by the present invention, a colony formation detection experiment is performed on the cells, and after the cells are cultured for 15 days, a typical morphology of the cells forming the colonies is observed under an inverted microscope;
[0064] In the figure, CFU-GEMM represents granulocyte-erythroid-macrophage-megakaryocyte colony-forming unit, BFU-E represents burst erythroid colony-forming unit, CFU-GM represents granulocyte-macrophage colony-forming unit, and CFU-MK represents megakaryocyte colony-forming unit.
[0065] Figure 8 The figures are statistical results of the types and numbers of colony-forming units of cells after 14 to 16 days of cell culture, when colony formation detection experiments were performed on cells on the 10th day of expansion culture using the in vitro expansion culture systems of hematopoietic stem cells provided in Examples 1 to 3 and Comparative Example 1, respectively;
[0066] In the figure, Control represents expansion culture system D1, ATRA represents expansion culture system 1, MSC Exo represents expansion culture system 2, and MSC Exo+ATRA represents expansion culture system 3;
[0067] CFU-GEMM stands for granulocyte-erythroid-macrophage-megakaryocyte colony-forming unit, BFU-E stands for burst erythroid colony-forming unit, CFU-GM stands for granulocyte-macrophage colony-forming unit, and CFU-MK stands for megakaryocyte colony-forming unit. DETAILED DESCRIPTION
[0068] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand.
[0069] Example 1
[0070] The in vitro expansion culture system 1 of umbilical cord blood-derived hematopoietic stem cells is composed of a basal culture medium, a cytokine combination and a small molecule compound ATRA; the cytokine combination is TPO, SCF, Flt3-L, IL-3 and IL-6; the concentration of each component is:
[0071] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, ATRA: 30nM.
[0072] Example 2
[0073] Umbilical cord blood-derived hematopoietic stem cell in vitro expansion culture system 2, composed of basal culture medium, cytokine combination and mesenchymal stem cell exosomes MSC-Exo; and the cytokine combination is TPO, SCF, Flt3-L, IL-3 and IL-6; the concentration of each component is:
[0074] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL.
[0075] Example 3
[0076] Umbilical cord blood-derived hematopoietic stem cell in vitro expansion culture system 3, composed of basal culture medium, cytokine combination and additives; the additives are composed of mesenchymal stem cell exosomes MSC-Exo and small molecule compound ATRA; the cytokine combination is TPO, SCF, Flt3-L, IL-3 and IL-6; the concentration of each component is:
[0077] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL, ATRA: 30nM.
[0078] Comparative Example 1
[0079] The in vitro expansion culture system D1 of umbilical cord blood-derived hematopoietic stem cells is composed of a basal culture medium and a cytokine combination; the cytokine combination is TPO, SCF, Flt3-L, IL-3 and IL-6; the concentration of each component is:
[0080] TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL.
[0081] The in vitro expansion and culture method for hematopoietic stem cells is carried out using the in vitro expansion and culture system provided in Examples 1-3 and Comparative Example 1, and the specific steps are as follows:
[0082] (1) Isolation of mononuclear cells from human umbilical cord blood samples
[0083] (1-1) Spray the blood donation bag containing the human umbilical cord blood sample from top to bottom with 75% alcohol and place it in a running biosafety cabinet. Use sterilized scissors to cut the plastic tube and transfer the human umbilical cord blood sample directly to a 50 mL centrifuge tube. Centrifuge at 2500g for 15 minutes, aspirate the upper layer of serum and transfer it to a new centrifuge tube to obtain the lower layer of whole blood cell sediment;
[0084] (1-2) resuspending the precipitate obtained in step (1-1) with DPBS at a volume ratio of 1:1, and then slowly adding the resuspended dilution to a sterile centrifuge tube containing 20 mL of Ficoll (human lymphocyte separation fluid) using a pipette, while slowly rotating the centrifuge tube at a constant speed. After the addition is completed, centrifuge the centrifuge tube at 800g for 20 minutes, and aspirate the buffy coat layer to obtain mononuclear cells;
[0085] (1-3) The mononuclear cell layer obtained in step (1-2) was transferred to a sterile centrifuge tube and supplemented with DPBS to 50 mL. The tube was centrifuged at 1200 g for 15 min, the supernatant was discarded, 50 mL of DPBS was added to the precipitate to wash the cells, the tube was centrifuged at 1200 g for 10 min, the supernatant was discarded, and the precipitate was taken. Finally, the tube was centrifuged with StemSpan TM Resuspend the pellet in SFEM basal medium and mix by pipetting to obtain a mononuclear cell suspension.
[0086] (2) Magnetic bead separation of CD34 + cell
[0087] (2-1) taking 20 μL of the mononuclear cell suspension obtained in step (1) into a cell counting plate and counting using a cell counter;
[0088] (2-2) According to every 1×10 8 Add 100 μL of PCR Blocking Reagent and 100 μL of CD34 MicroBeads to the cells, mix well and incubate in a 4°C refrigerator for 30 min. 8 Add 5-10 mL of hematopoietic stem cell sorting buffer to wash the cells, centrifuge at 800 g for 10 min at room temperature, discard the supernatant, and transfer 1×10 8 The cells were resuspended in 500 μL of buffer;
[0089] (2-3) Install the sorting column of the CD34 magnetic bead sorting kit on the sorter, rinse the sorting column with hematopoietic stem cell sorting buffer, add the cell suspension to the sorting column, and collect the unlabeled cells that flow through the sorting column: wash the sorting column 3 times with 1mL of hematopoietic stem cell sorting buffer. Collect the unlabeled cells that flow through the sorting column. Remove the sorting column from the sorter and place it on an appropriate collection tube. Take 1mL of hematopoietic stem cell sorting buffer and add it to the sorting column. Use a uniform force to push the piston to the bottom of the sorting column to push out all the target cells, and obtain CD34 + Cells were sampled for counting.
[0090] (3) Expansion and culture of CD34 + cell
[0091] The in vitro hematopoietic stem cell expansion culture systems provided in Examples 1 to 3 and Comparative Example 1 were respectively used to resuspend the CD34 + cells, and at 2×10 4 The cells were inoculated at a density of 10 cells / mL in a 12-well cell culture plate and cultured and expanded to obtain the expanded CD34 + cell.
[0092] In the above examples and comparative examples, cytokines were purchased from Thermo Fisher Scientific; human umbilical cord blood samples and human umbilical cord were from the biological sample bank; StemSpan TM SFEM basal culture medium was purchased from STEMCELL, and other raw materials, reagents, solvents, etc. used can be obtained commercially.
[0093] The in vitro expansion culture system provided in the above-mentioned embodiments and comparative examples is used to perform in vitro expansion detection of hematopoietic stem cells.
[0094] 1. In vitro amplification efficiency detection experiment
[0095] The in vitro expansion and culture system methods of hematopoietic stem cells provided in Examples 1-3 and Comparative Example 1 were used to detect the cell number and stemness maintenance effect of the obtained hematopoietic stem cells. The detection method was as follows:
[0096] The hematopoietic stem cells were cultured in vitro for 10 days using the hematopoietic stem cell in vitro expansion culture system provided in Examples 1-3 and Comparative Example 1. The hematopoietic stem cells were incubated with antibodies using CD34-FITC, CD38-PE, Lin-APC and CD45-FITC antibodies, and the hematopoietic stem cells were analyzed using a flow cytometer. The total nucleated cell count in each example was then counted. The CD34-PE, CD38-PE, Lin-APC and CD45-FITC antibodies were incubated with antibodies using the flow cytometer. + Cells, CD34 + CD38 - Cells and CD34 + CD38 - Lin - The number of cells was statistically detected. Flow cytometry analysis showed that the initial inoculation density of Examples 1-3 and Comparative Example 1 on day 0 was 2×10 total nucleated cells (TNCs). 4 cell / mL, and the CD34 + The cell ratio must be above 90%. The hematopoietic stem cell culture system provided in each of Examples 1-3 and Comparative Example 1 was used to expand in vitro for 5 (D5) and 10 days (D10), and samples were taken to count the total nucleated cells (TNCs); and on the 10th day of in vitro expansion culture, TNCs, CD34+ Cells, CD34 + CD38 - Cells and CD34 + CD38 - Lin - The number of cells was analyzed and counted by flow cytometry. The counting and analysis results of flow cytometry are shown in Table 1.
[0097] Table 1 Cell count results of total nucleated cells (TNCs) of Comparative Example 1 and Examples 1-3 after 5 and 10 days of expansion
[0098]
[0099] According to the test results in Table 1, the total nucleated cell counts (TNCs) of hematopoietic stem cells obtained after 5 days of culture using the hematopoietic stem cell in vitro expansion culture system methods provided in Comparative Example 1, Example 1, Example 2, and Example 3 were 1.04-1.26×10 6 , 2.59~3.01×10 6 1.26~1.48×10 6 , 1.67~1.93×10 6 , and the hematopoietic stem cell in vitro expansion and culture methods provided by Comparative Example 1, Example 1, Example 2 and Example 3 were respectively used to expand the TNCs cells in vitro for 5 days, and the expansion times were 52 to 63 times, 130 to 151 times, 63 to 74 times, and 84 to 97 times, respectively;
[0100] Using the in vitro expansion culture system of hematopoietic stem cells provided in Comparative Example 1, Example 1, Example 2 and Example 3, after 10 days of culture, the total nucleated cell count (TNCs) of hematopoietic stem cells obtained were 2.20-2.88×10 6 、6.21~7.11×10 6 4.16~5.00×10 6 5.23~5.62×10 6 , and the expansion times of TNCs cells after 10 days of in vitro expansion by the in vitro expansion and culture methods of hematopoietic stem cells provided in Comparative Example 1, Example 1, Example 2 and Example 3 were 110-144 times, 311-356 times, 208-250 times and 262-281 times respectively. It can be seen from the above that the expansion times of TNCs cells in vitro by the in vitro expansion and culture methods of hematopoietic stem cells in this embodiment are much higher than those in Comparative Example 1.
[0101] Table 2 Flow counting and analysis results of comparative example 1 and examples 1-3 obtained by in vitro amplification for 10 days
[0102]
[0103] According to Table 2 and Figures 1 to 6 The test results show that the CD34 + The number of cells was 4.86~6.36×10 5 1.20~1.37×10 6 , 1.34~1.61×10 6 , 1.57~1.69×10 6 ; and respectively adopt the in vitro expansion and culture methods of hematopoietic stem cells provided in Comparative Example 1, Example 1, Example 2, and Example 3, and expand CD34 + The cell mass expansion multiples were 27-35 times, 66-76 times, 74-89 times, and 87-94 times, respectively. Using the hematopoietic stem cell in vitro expansion culture system method provided in Comparative Example 1, Example 1, Example 2, and Example 3, after culturing for 10 days, the obtained CD34 + CD38 - The number of cells was 0.73~0.95×10 4 , 1.74~1.99×10 4 1.30~1.55×10 4 , 2.98~3.20×10 4 ; and respectively adopt the in vitro expansion and culture methods of hematopoietic stem cells provided in Comparative Example 1, Example 1, Example 2 and Example 3, and expand in vitro for 10 days, CD34 + CD38 - The cell mass expansion multiples were 17-22 times, 40-46 times, 30-36 times, and 69-75 times, respectively. Using the hematopoietic stem cell in vitro expansion culture system method provided in Comparative Example 1, Example 1, Example 2, and Example 3, after culturing for 10 days, the obtained CD34 + CD38 - Lin - The number of cells was 0.40~0.52×10 4 , 0.75~0.85×10 4 , 0.87~1.05×10 4 , 1.52~1.63×10 4 ; and respectively adopt the in vitro expansion and culture methods of hematopoietic stem cells provided in Comparative Example 1, Example 1, Example 2 and Example 3 to expand in vitro for 10 days CD34 + CD38 - Lin - The cell mass expansion multiples were 40-52 times, 75-85 times, 87-105 times, and 152-162 times, respectively.
[0104] Therefore, compared with Comparative Example 1, the in vitro expansion culture system of hematopoietic stem cells used in Examples 1-3 has a significant difference in TNCs, CD34 + 、CD34 + CD38 - and CD34 + CD38 - Lin - The in vitro expansion efficiency of cells was significantly improved. In addition, the in vitro expansion culture system of hematopoietic stem cells used in Example 3 showed good effects in maintaining cell stemness, such as CD34 + 、CD34 + CD38 - and CD34 + CD38 - Lin - The cell amount was the highest among all example groups.
[0105] 2. Differentiation Potential Detection
[0106] For the in vitro expansion and culture methods of hematopoietic stem cells provided in Examples 1-3 and Comparative Example 1, respectively, after in vitro culture, the hematopoietic stem cells obtained were subjected to a differentiation potential detection experiment, and the detection method is as follows:
[0107] Using the in vitro expansion and culture methods of hematopoietic stem cells provided in Examples 1-3 and Comparative Example 1, after the hematopoietic stem cells were expanded in vitro for 10 minutes, cell samples were taken and inoculated into MethoCult culture medium for culture, and the colony formation ability of cells was tested. The test results are shown in Table 3.
[0108] Cell colony formation assay is a conventional method to identify the in vitro differentiation potential of HSCs. For hematopoietic stem cells derived from umbilical cord blood, CFU identification includes CFU-MK (megakaryocyte colony forming unit), CFU-GM (granulocyte-macrophage colony forming unit), BFU-E (burst erythroid colony forming unit), CFU-GEMM (granulocyte-erythroid-macrophage-megakaryocyte colony forming unit), etc.
[0109] Table 3 Colony forming unit detection results of hematopoietic stem cells obtained in Comparative Example 1 and Examples 1-3
[0110]
[0111]
[0112] According to Table 3 and Figures 7-8The test results show that, using the in vitro expansion and culture method for hematopoietic stem cells provided in Comparative Example 1 of the present invention, the hematopoietic stem cells obtained after 10 days of in vitro expansion and culture were inoculated into MethoCult culture medium for cell colony formation test results, showing that the number of CFU-MK was 36-42, the number of CFU-GM was 33-36, the number of BFU-E was 10-15, and the number of CFU-GEMM was 7-11;
[0113] The hematopoietic stem cells obtained after 10 days of culture using the in vitro expansion and culture method of hematopoietic stem cells provided in Example 1 were subjected to cell colony formation detection and analysis. The results showed that the number of CFU-MK was 38-48, the number of CFU-GM was 39-43, the number of BFU-E was 13-17, and the number of CFU-GEMM was 9-14.
[0114] The results of the colony-forming cell detection and analysis of the hematopoietic stem cells obtained after culturing for 10 days using the hematopoietic stem cell method provided in Example 2 showed that the number of CFU-MK was 44-48, the number of CFU-GM was 40-45, the number of BFU-E was 14-21, and the number of CFU-GEMM was 11-16;
[0115] The hematopoietic stem cells obtained after 10 days of culture using the in vitro expansion and culture method for hematopoietic stem cells provided in Example 3 were subjected to cell colony formation detection and analysis. The results showed that the number of CFU-MK was 41-47, the number of CFU-GM was 39-47, the number of BFU-E was 14-19, and the number of CFU-GEMM was 11-18.
[0116] Comprehensive analysis showed that the TNCs and CD34 + 、CD34 + CD38 - and CD34 + CD38 - Lin - The cell amount was significantly higher than that of comparative example 1, and there was a significant difference. This shows that the schemes of Examples 1-3 can significantly promote the in vitro expansion of hematopoietic stem cells. Compared with Examples 1-2, Example 3 found that the CD34 + 、CD34 + CD38 - and CD34 + CD38 - Lin - The cell amount is higher than that of Examples 1-2. This shows that Example 3 has the best effect on maintaining the stemness of hematopoietic stem cells while promoting the in vitro expansion of hematopoietic stem cells among the three examples. In addition, in the flow analysis results of Example 3 on D10, CD34+ The positive rate reached 30.03%, which was higher than that of Examples 1-2 and Comparative Example 1. In addition, the CFU test results of Example 3 also showed good in vitro differentiation potential.
[0117] Therefore, it is demonstrated that the hematopoietic stem cell in vitro expansion culture system adopted in Example 3 can efficiently expand hematopoietic stem cells in vitro while also well maintaining the in vitro differentiation potential of the expanded hematopoietic stem cells, which is of great significance for improving the success rate of transplantation in clinical applications.
[0118] Although the above embodiments have been described in detail, they are only a part of the embodiments of the present invention, not all of them. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all belong to the protection scope of the present invention.
Claims
1. An in vitro expansion and culture system for hematopoietic stem cells derived from umbilical cord blood, characterized in that: The hematopoietic stem cell in vitro expansion culture system is composed of a basal culture medium, a cytokine combination and an additive; the additive is a mesenchymal stem cell exosome MSC-Exo or a small molecule compound ATRA or a combination of a mesenchymal stem cell exosome MSC-Exo and a small molecule compound ATRA; the cytokine combination is TPO, SCF, Flt3-L, IL-3 and IL-6; the concentration of each component is: TPO: 50-100ng / mL, SCF: 50-100ng / mL, Flt3-L: 50-100ng / mL, IL-3: 10-20ng / mL, IL-6: 10-30ng / mL, MSC-Exo: 50-200μg / mL and ATRA: 10-50nM.
2. The in vitro expansion culture system of hematopoietic stem cells derived from umbilical cord blood according to claim 1, characterized in that: The additive is mesenchymal stem cell exosomes MSC-Exo or a small molecule compound ATRA or a combination of mesenchymal stem cell exosomes MSC-Exo and a small molecule compound ATRA. The concentration of each component in the in vitro expansion culture system is: TPO: 50-70ng / mL, SCF: 50-70ng / mL, Flt3-L: 50-80ng / mL, IL-3: 8-15ng / mL, IL-6: 5-15ng / mL, MSC-Exo: 100-150μg / mL, ATRA: 20-30nM.
3. The in vitro expansion culture system of hematopoietic stem cells derived from umbilical cord blood according to claim 2, characterized in that: The hematopoietic stem cell in vitro expansion culture system is composed of a basal culture medium, a cytokine combination and an additive; the additive is a combination of mesenchymal stem cell exosomes MSC-Exo and a small molecule compound ATRA. The concentration of each component in the hematopoietic stem cell in vitro expansion culture system is: TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL, ATRA: 30nM.
4. The in vitro expansion culture system of hematopoietic stem cells derived from umbilical cord blood according to claim 2, characterized in that: The hematopoietic stem cell in vitro expansion culture system is composed of a basal culture medium, a cytokine combination and mesenchymal stem cell exosomes MSC-Exo; the concentration of each component in the hematopoietic stem cell in vitro expansion culture system is: TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL.
5. The in vitro expansion culture system of hematopoietic stem cells derived from umbilical cord blood according to claim 2, characterized in that: The hematopoietic stem cell in vitro expansion culture system is composed of a basic culture medium, a cytokine combination and a small molecule compound ATRA; the concentration of each component in the hematopoietic stem cell in vitro expansion culture system is: TPO: 50ng / mL, SCF: 50ng / mL, Flt3-L: 50ng / mL, IL-3: 10ng / mL, IL-6: 10ng / mL, MSC-Exo: 100μg / mL, ATRA: 30nM.
6. The in vitro expansion and culture system of hematopoietic stem cells derived from umbilical cord blood according to any one of claims 1 to 5, characterized in that: The basic culture medium is a serum-free culture medium.
7. The in vitro expansion and culture system of hematopoietic stem cells derived from umbilical cord blood according to claim 6, characterized in that: The serum-free medium is selected from StemSpan TM SFEM, IMDM, DMEM / F-12, RPMI 1640 and HyClone Advance STEM.
8. A method for in vitro expansion and culture of hematopoietic stem cells derived from human umbilical cord blood, characterized in that: The following steps are involved: (1) Pre-treating a human umbilical cord blood sample, and then sequentially resuspending, centrifuging, extracting, washing, and resuspending to obtain a mononuclear cell suspension; (2) Count and resuspend the mononuclear cell suspension, add CD34 MicroBeads and PcRBlocking Reagent to the cell suspension, and then pass through the column for CD34 + Positive sorting, CD34 + Cell suspension with high proportion; (3) Hematopoietic stem cell in vitro expansion culture system resuspends the CD34 + The cell suspension with a high proportion is inoculated into a cell culture flask for culture and expansion.
